More severe comorbidities, advanced age, and incomplete vaccination increase the risk of COVID-19 mortality
- PMID: 39280314
- PMCID: PMC11391969
- DOI: 10.52225/narra.v4i2.949
More severe comorbidities, advanced age, and incomplete vaccination increase the risk of COVID-19 mortality
Abstract
Numerous studies have stated that comorbidities are risk factors for coronavirus disease 2019 (COVID-19) mortality, but few have considered the severity or stage of these comorbidities. The aim of this study was to determine the association between the severity of comorbidity, age, and number of COVID-19 vaccinations with COVID-19 mortality. This case-control study was conducted from July 2021 until December 2022 at the Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. The patients were divided into non-survived patients (case group) and survived patients (control group). The inclusion criteria for cases were adult patients hospitalized with confirmed COVID-19, based on reverse transcriptase-polymerase chain reaction (RT-PCR) testing of nasopharyngeal swabs. Using total sampling, 1,046 confirmed COVID-19 patients, which consisted of 450 (43%) non-survived patients and 596 (57%) survived patients, were included. The most common comorbidity was diabetes mellitus (DM) (82.7%), chronic kidney disease (CKD) (43%), hypertension (25.7%), and obesity (23.6%). Our multivariate analysis indicated that older age (aOR: 1.03; 95%CI: 1.02-1.04, p<0.001), male sex (aOR: 1.29; 95%CI: 1.11- 2.00, p=0.007), severe COVID-19 at first admission (aOR: 3.13; 95%CI: 2.08-4.73, p<0.001), having pneumonia (aOR: 1.99; 95%CI: 1.21-3.33, p=0.005), poorly controlled DM with HbA1c≥9% (aOR: 2.90; 95%CI: 1.72-4.89, p<0.001), severe obesity with body mass index (BMI)≥30 (OR: 2.90; 95%CI: 1.72-4.89, p<0.001), hypertension stage 2 (aOR: 1.99; 95%CI: 1.12-3.53, p=0.019) or stage 3 (aOR: 6.59; 95%CI: 2.39-18.17, p<0.001), CKD stage 3 (aOR: 2.50; 95%CI: 1.36-4.59, p=0.003), stage 4 (aOR: 5.47; 95%CI: 2.18-13.69, p<0.001) or stage 5 (aOR: 1.71; 95%CI: 1.04-2.81, p=0.036), and having chronic lung disease (aOR: 3.08; 95%CI: 1.22-7.77, p=0.017) significantly increased the risk of COVID-19 mortality. In contrast, COVID-19 vaccination reduced the risk of COVID-19-associated death. This study highlights that more severe comorbidities, advanced age, and incomplete vaccination were associated with COVID-19 mortality.
Keywords: COVID-19; mortality; risk factor; severity; vaccination.
© 2024 The Author(s).
Conflict of interest statement
All the authors declare that there are no conflicts of interest.
Figures
Similar articles
-
Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study.PLoS One. 2021 Oct 5;16(10):e0258154. doi: 10.1371/journal.pone.0258154. eCollection 2021. PLoS One. 2021. PMID: 34610047 Free PMC article.
-
A national population-based study of mortality and risk factors in COVID-19-hospitalized patients in Spain (2020-2021).Front Public Health. 2025 Feb 4;13:1488283. doi: 10.3389/fpubh.2025.1488283. eCollection 2025. Front Public Health. 2025. PMID: 39980912 Free PMC article.
-
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.Clin Rheumatol. 2020 Sep;39(9):2789-2796. doi: 10.1007/s10067-020-05301-2. Epub 2020 Jul 27. Clin Rheumatol. 2020. PMID: 32720259 Free PMC article.
-
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.JAMA Netw Open. 2021 Mar 1;4(3):e213594. doi: 10.1001/jamanetworkopen.2021.3594. JAMA Netw Open. 2021. PMID: 33787911 Free PMC article.
-
Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients.PLoS One. 2020 Dec 7;15(12):e0243191. doi: 10.1371/journal.pone.0243191. eCollection 2020. PLoS One. 2020. PMID: 33284825 Free PMC article.
Cited by
-
Assessment of the relationship between hematologic parameters, (CPD), in screening for COVID-19 severity in women.Future Sci OA. 2025 Dec;11(1):2540749. doi: 10.1080/20565623.2025.2540749. Epub 2025 Aug 2. Future Sci OA. 2025. PMID: 40752013 Free PMC article.
References
-
- Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China. Jama 2020;323(13):1239. - PubMed
-
- United Nations International Children’s Emergency Fund. COVID-19 Vaccine Acceptance Survey in Indonesia. Jakarta; UNICEF Indonesia: 2020.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical